Higher patient cost-sharing is associated with a lower likelihood of treatment augmentation in patients with depression who are treated with antidepressants.
Zhun Cao, PhD
Advertisement
Articles by Zhun Cao, PhD
Prior authorization for pregabalin in commercial insurance plans accomplished the objective of lower pregabalin utilization; however, there was no significant decrease in disease-related healthcare costs.
Advertisement
Latest Updated Articles
- Healthcare Utilization and Cost Effects of Prior Authorization for Pregabalin in Commercial Health Plans
Published: June 10th 2010 | Updated:
- Impact of Cost-Sharing on Treatment Augmentation in Patients With Depression
Published: January 16th 2012 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
Newly Unveiled ACA Premiums Show 26% Average Increase Before Subsidy Expiration
2
New PBM Laws Seek to Protect Independent Pharmacies but Could Raise Costs, Limit Patient Access
3
FDA Guidance to Remove One of the Largest Barriers to Biosimilar Development
4
Boosting RSV Vaccination in Older Adults Could Save Thousands
5
